Beta
Trial Radar KI
Eine Studie entspricht den Filterkriterien
Kartenansicht
Zurück zur Suche

Assess Impact of Poly-L-lactic Acid on GLP1 Subjects Phase 2 20

Noch nicht rekrutierend
Die Details der klinischen Studie sind hauptsächlich auf Englisch verfügbar. Trial Radar KI kann jedoch helfen! Klicken Sie einfach auf 'Studie erklären', um die Informationen zur Studie in der ausgewählten Sprache anzuzeigen und zu besprechen.
Die klinische Studie NCT07217743 untersucht Behandlung im Zusammenhang mit Hautlaxität. Diese interventionsstudie der Phase 2 hat den Status noch nicht rekrutierend. Der Start ist für 27. Oktober 2025 geplant, bis 20 Teilnehmer aufgenommen werden. Durchgeführt von Goldman, Butterwick, Fitzpatrick and Groff wird der Abschluss für 31. Oktober 2026 erwartet. Die Daten von ClinicalTrials.gov wurden zuletzt am 16. Oktober 2025 aktualisiert.
Kurzbeschreibung
Clinical trial to evaluate treatments of double-dilute poly-L-lactic acid on abdominal skin laxity in GLP1 patients versus non GLP1 patients.
Ausführliche Beschreibung
20 patients total (15 GLP1 and 5 non-GLP1) will receive three treatments of double-dilute PLLA (Sculptra® Aesthetic; Galderma Laboratories; Fort Worth, TX) to the abdomen one month apart. Using a 22 G 2" cannula, up to 16cc of poly-L-lactic acid will be used per treatment. Patients will return for follow up visits at month 3 and month 9, where they will undergo standardized 2D photography and assessments.
Offizieller Titel

Prospective, Single Center, Open-label Study Assessing Impact of Poly-L-lactic Acid on Adipogenesis in Patients on Glucagon-like Peptide-1 Agonists

Erkrankungen
Hautlaxität
Weitere Studien-IDs
  • Sculptra-Aesthetic-GLP1
NCT-Nummer
NCT07217743
Studienbeginn (tatsächlich)
2025-10-27
Zuletzt aktualisiert
2025-10-16
Studienende (vorauss.)
2026-10-31
Geplante Rekrutierung
20
Studientyp
Interventionsstudie
PHASE
Phase 2
Status
Noch nicht rekrutierend
Stichwörter
laxity
loose skin
glp1
abdominal laxity
Primäres Ziel
Behandlung
Zuteilungsmethode
Nicht randomisiert
Interventionsmodell
Parallel
Verblindung
Keine (offene Studie)
Studienarme/Interventionen
Teilnehmergruppe/StudienarmIntervention/Behandlung
Aktives VergleichspräparatGLP1 Patients
15 Participants who have been on a stable dose of GLP1 for at least 6 months will receive three treatments, one month apart, of Sculptra Aesthetic up to 16cc.
Sculptra Aesthetic
15 GLP1 subjects treated with Sculptra to their abdomen for skin laxity will be compared to 5 non GLP1 subjects treated with Sculptra for skin laxity.
ExperimentellNON GLP1 Patients
5 participants who are GLP1 naive will receive three treatments, one month apart, of Sculptra Aesthetic up to 16cc.
Sculptra Aesthetic
15 GLP1 subjects treated with Sculptra to their abdomen for skin laxity will be compared to 5 non GLP1 subjects treated with Sculptra for skin laxity.
Hauptergebnismessungen
ErgebnismessungBeschreibung der MessungZeitrahmen
Physical Global Aesthetic Improvement Scale
Assess improvement of Abdominal skin laxity: Much Improved 2 Improved 1 No Change 0 Worse -1 Much Worse -2
Month 3 and Month 9
Nebenergebnismessungen
ErgebnismessungBeschreibung der MessungZeitrahmen
Subject Global Aesthetic Improvement Scale
Assess improvement of Abdominal skin laxity: Much Improved 2 Improved 1 No Change 0 Worse -1 Much Worse -2
Month 3 and Month 9
Teilnahme-Assistent
Eignungskriterien

Zugelassene Altersgruppen
Erwachsene, Ältere Erwachsene
Mindestalter
25 Years
Zugelassene Geschlechter
Weiblich
Akzeptiert gesunde Freiwillige
Ja

  1. Adult women aged 25-65 years.

  2. Fitzpatrick skin types I-IV.

  3. Presence of mild to moderate skin laxity of abdomen, as determined by clinical investigators.

  4. Stable weight for 3 months, with body mass index (BMI) of 27 or less.

  5. Current treatment with a stable dose of GLP-1 agonist medication for at least the last 6 months, for 15 of the enrolled subjects. Remaining 5 subjects should not be taking or have a history of taking a GLP-1 agonist medication, and should not be planning to take a GLP-1 in the foreseeable future.

  6. Must be willing to sign a photography release and ICF, and complete the entire course of the study.

  7. Subjects in good general health based on investigator's judgment and medical history.

  8. Negative urine pregnancy test result at the time of study entry (if applicable).

  9. Subjects of childbearing potential must agree to use an effective method of birth control during the entire course of the study. All systemic birth control measures must be in consistent use for at least 30 days prior to study enrollment.

    1. Acceptable forms of birth control are: oral contraceptive pill, injection, implant, patch, vaginal ring, intrauterine device/coil, double-barrier methods (e.g., sponge, spermicide, or condoms). Abstinence and/or vasectomized partner must agree to a second acceptable method of birth control (double-barrier) should the subject become sexually active.
    2. A female is considered of non-childbearing potential if she is: postmenopausal (no menses for at least 12 months), without a uterus (hysterectomy) and/or both ovaries (oophorectomy), or bilateral tubal ligation.

  1. The presence of severe abdominal skin laxity as determined by clinical investigators.
  2. Still actively losing weight.
  3. Pregnancy or planned pregnancy during the study or currently breastfeeding.
  4. Any uncontrolled systemic disease.
  5. History of autoimmune connective tissue disease.
  6. Current use of immunosuppressive medication.
  7. Significant history or current evidence of a medical, psychological or other disorder that, in the investigator's opinion, would preclude enrollment into the study.
  8. Active dermatitis or active infection in the proposed treatment area.
  9. Mesotherapy; dermal fillers, biostimulator injectables; radiofrequency device treatments; microfocused ultrasound device treatments; laser and light-based device treatments; microneedling; cryolipolysis; high intensity focused electromagnetic energy device treatment; or surgery during the 12-month period before study treatment.
  10. Any investigational treatment for skin quality of the abdomen during the 12-month period before the study treatment
  11. Creams/cosmeceuticals and/or home therapies for the prevention or treatment of skin quality in the treatment area during the 1-month period before study treatment
  12. Subjects with scarring in the treatment areas, including laparoscopic or abdominal surgery scars, which in the opinion of the investigator could impact results. Subjects with a history of keloids will be excluded.
  13. Subjects who spray tanned or used sunless tanners in the treatment areas 1-month prior to study treatment.
  14. History of bleeding disorder, concomitant use of anticoagulants, history of connective tissue disease (e.g., lupus, scleroderma), history of Bell's Palsy, epilepsy, smoking, and/or current pregnancy or breastfeeding .
  15. Inability to ambulate following the procedure.
  16. History of lidocaine and/or epinephrine sensitivity deemed by the investigator to preclude subject from enrolling into study.
  17. Individuals with known allergies or sensitivities to any of the ingredients of any topical or injectable products being used in this study.
  18. Current participation or participation within 30 days prior to the start of this study in a drug or other investigational research study.
Goldman, Butterwick, Fitzpatrick and Groff logoGoldman, Butterwick, Fitzpatrick and Groff
Zentrale Studienkontakte
Kontakt: Andrea Pacheco, 858-657-1004, [email protected]
1 Studienstandorte in 1 Ländern

California

West Dermatology Research Center, San Diego, California, 92121, United States
Andrea Pacheco, Kontakt, 858-657-1004, [email protected]
Freia Canals-Cistero, Kontakt, 858-657-1004, [email protected]